FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc., resulting in labeling changes for its multiple sclerosis indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

SUPPL AP for OCREVUS (OCRELIZUMAB)